ES2241507T1 - Nuevas formas de cristal de atorvastatina semicalcica y procedimientos para su preparacion, asi como nuevos procedimientos para la preparacion de las formas i, viii y ix de atorvastatina semicalcica. - Google Patents

Nuevas formas de cristal de atorvastatina semicalcica y procedimientos para su preparacion, asi como nuevos procedimientos para la preparacion de las formas i, viii y ix de atorvastatina semicalcica.

Info

Publication number
ES2241507T1
ES2241507T1 ES03713610T ES03713610T ES2241507T1 ES 2241507 T1 ES2241507 T1 ES 2241507T1 ES 03713610 T ES03713610 T ES 03713610T ES 03713610 T ES03713610 T ES 03713610T ES 2241507 T1 ES2241507 T1 ES 2241507T1
Authority
ES
Spain
Prior art keywords
atorvastatin
semi
calcic
approximately
characteristic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES03713610T
Other languages
English (en)
Spanish (es)
Inventor
Limor Tessler
Judith Aronhime
Revital Lifshitz-Liron
Dalia Maidan-Hanoch
Nir Hasson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of ES2241507T1 publication Critical patent/ES2241507T1/es
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C07D207/327Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
ES03713610T 2002-02-15 2003-02-19 Nuevas formas de cristal de atorvastatina semicalcica y procedimientos para su preparacion, asi como nuevos procedimientos para la preparacion de las formas i, viii y ix de atorvastatina semicalcica. Pending ES2241507T1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35718102P 2002-02-15 2002-02-15
US357181P 2002-02-15
US42532502P 2002-11-12 2002-11-12
US425325P 2002-11-12

Publications (1)

Publication Number Publication Date
ES2241507T1 true ES2241507T1 (es) 2005-11-01

Family

ID=27760457

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03713610T Pending ES2241507T1 (es) 2002-02-15 2003-02-19 Nuevas formas de cristal de atorvastatina semicalcica y procedimientos para su preparacion, asi como nuevos procedimientos para la preparacion de las formas i, viii y ix de atorvastatina semicalcica.

Country Status (14)

Country Link
EP (1) EP1480950A4 (no)
JP (2) JP2005519076A (no)
KR (1) KR100724515B1 (no)
CN (1) CN100406436C (no)
AU (1) AU2003217653A1 (no)
CA (1) CA2475864A1 (no)
DE (1) DE03713610T1 (no)
ES (1) ES2241507T1 (no)
HR (1) HRP20040768A2 (no)
IS (1) IS7402A (no)
MX (1) MXPA04007939A (no)
NO (1) NO20043842L (no)
PL (1) PL372303A1 (no)
WO (1) WO2003070702A1 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
WO2003070665A2 (en) 2002-02-19 2003-08-28 Teva Pharmaceutical Industries Ltd. Desolvating solvates of atorvastatin hemi-calcium
CA2508871C (en) * 2002-11-28 2008-09-09 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
WO2006011041A2 (en) 2004-07-20 2006-02-02 Warner-Lambert Company Llc Crystalline forms of (r-(r*))-2-(4-fluorophenyl)-beta, gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-hept anoic acid calcium salt (2:1)
EP1711464A2 (en) * 2004-07-22 2006-10-18 Teva Pharmaceutical Industries Ltd Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation
WO2006048894A1 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Novel crystalline forms of atorvastatin calcium and processes for preparing them.
WO2006106372A1 (en) * 2005-04-08 2006-10-12 EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság New crystalline atorvastatin hemicalcium salt polymorph form
DK1957452T3 (da) 2005-11-21 2010-07-26 Warner Lambert Co Nye former af [R-(R*,R*)]-2-(4-fluorphenyl)-B,B-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptansyre- magnesium
US8080672B2 (en) 2005-12-13 2011-12-20 Teva Pharmaceutical Industries Ltd. Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
US20070265456A1 (en) * 2006-05-09 2007-11-15 Judith Aronhime Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
WO2008108572A1 (en) * 2007-03-02 2008-09-12 Dong-A Pharm. Co., Ltd. Novel crystal forms of pyrrolylheptanoic acid derivatives
KR20120011249A (ko) * 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
KR101324862B1 (ko) * 2011-07-12 2013-11-01 (주)에이에스텍 클로피도그렐 황산수소염의 구형 입자, 이를 포함하는 약학적 조성물 및 이의 제조방법
MA39033A1 (fr) 2013-11-15 2017-11-30 Akebia Therapeutics Inc Formes solides d'acide {[5-(3-chlorophényl)-3-hydroxypyridine-2-carbonyl] amino}acétique, compositions et leurs utilisations
CN105055357A (zh) * 2015-09-25 2015-11-18 青岛华之草医药科技有限公司 一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂
KR101723783B1 (ko) * 2017-02-24 2017-04-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003959A1 (en) * 1995-07-17 1997-02-06 Warner-Lambert Company Crystalline [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
CN1423634A (zh) * 1999-11-17 2003-06-11 特瓦制药工业有限公司 阿托伐他汀钙的多晶型物
MXPA02004078A (es) * 1999-12-17 2002-10-11 Warner Lambert Res & Dev Un proceso a escala industrial para producir sal de hemi calcio de trihidrato de atorvastatin cristalino.
ES2258030T3 (es) * 1999-12-17 2006-08-16 Pfizer Science And Technology Ireland Limited Procedimiento para producir atorvastatina calcio cristalina.
SK6592003A3 (en) * 2000-11-03 2004-01-08 Teva Pharma Atorvastatin hemi-calcium form VII
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
MXPA03005879A (es) * 2000-12-27 2003-09-10 Ciba Sc Holding Ag Formas cristalinas de atorvastatina.
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
GEP20053546B (en) * 2001-06-29 2005-06-10 Warner Lambert Co Crystalline Forms of 'R-(R*,R*)!-2-(4- Fluorophenyl)-Beta, Delta-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-'Phenylamino) Carbonyl!-1H-Pyrrole-1-Heptanoic Acid Calcium Salt (2:1) (Atorvastatin)
IL159626A0 (en) * 2001-07-30 2004-06-01 Reddys Lab Ltd Dr Crystalline forms of atorvastatin calcium and processes for the preparation thereof
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
WO2004022053A1 (en) * 2002-09-03 2004-03-18 Morepen Laboratories Limited Atorvastatin calcium form vi or hydrates thereof
CA2508871C (en) * 2002-11-28 2008-09-09 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt

Also Published As

Publication number Publication date
JP2005519076A (ja) 2005-06-30
WO2003070702A1 (en) 2003-08-28
CA2475864A1 (en) 2003-08-28
KR20040081202A (ko) 2004-09-20
PL372303A1 (en) 2005-07-11
NO20043842L (no) 2004-09-14
JP2009235083A (ja) 2009-10-15
HRP20040768A2 (en) 2005-06-30
AU2003217653A1 (en) 2003-09-09
CN100406436C (zh) 2008-07-30
EP1480950A1 (en) 2004-12-01
IS7402A (is) 2004-08-13
MXPA04007939A (es) 2004-11-26
DE03713610T1 (de) 2005-10-20
CN1646490A (zh) 2005-07-27
KR100724515B1 (ko) 2007-06-04
EP1480950A4 (en) 2005-05-18

Similar Documents

Publication Publication Date Title
ES2241507T1 (es) Nuevas formas de cristal de atorvastatina semicalcica y procedimientos para su preparacion, asi como nuevos procedimientos para la preparacion de las formas i, viii y ix de atorvastatina semicalcica.
ES2608961T3 (es) Nueva forma cristalina VI de agomelatina, procedimiento para su preparación y composiciones farmacéuticas que la contienen
ES2391406T3 (es) Nueva forma cristalina V de la agomelatina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
ES2718926T3 (es) Formas polimórficas de 3-(4-amino-1-oxo-1,3-dihidroisoindol-2-il)piperidin-2,6-diona
BR112018071585B1 (pt) Formulações de um inibidor de lsd1, seus usos e método de preparação das mesmas
ES2382806T3 (es) Compuesto ácido ciclohexanocarboxílico
JP2023116645A (ja) フリー体のクリサボロールの結晶形ならびにそれらの調製方法および使用
JP2006104184A (ja) ストロンチウムラネレートのアルファー(α)−結晶形、その製造方法、及びそれを含む医薬組成物
ES2694512T3 (es) Procedimiento mejorado para la preparación de pomalidomida y su purificación
ES2356838T5 (es) Base cristalina de escitalopram y comprimidos orodispersables que contienen escitalopram
JP4180368B2 (ja) 塩酸ベンラファキシンの結晶形
PT106142B (pt) Processo para a preparação de brometo de tiotrópio
ES2671608T3 (es) Formas sólidas de 3-(4-nitro-1-oxoisoindolin-2-il)piperidina-2,6-diona
JP2014516341A (ja) アゴメラチンの新しい結晶形vii、その調製方法及び使用並びにこれを含有する医薬組成物
ES2315141A1 (es) Procedimiento para la preparacion de cardesartan cilexetilo en forma cristalina.
ES2308304T3 (es) Procedimientos de preparacion de la olanzapina.
KR20130136546A (ko) 혼합된 결정성 아고멜라틴 (형태-viii), 및 이의 제조 방법 및 용도 및 이를 함유하는 약학적 조성물
ES2303768B1 (es) Nueva forma cristalina de moxifloxacino clorhidrato.
ES2815924T3 (es) Forma D1 cristalina altamente estable de la sal de monoetanolamina de eltrombopag
CA1116629A (en) Troponyl-oxamic acid derivatives and process therefor
ES2553574T3 (es) Polimorfos de un principio activo farmacéutico
KR860001228B1 (ko) d-및 l-2-(6-메톡시-2-나프틸)-프로피온산 혼합물의 광학적 분할방법
ES2534318B1 (es) Derivados de cromeno sustituidos por alcóxido como inhibidores de la interacción TCR-Nck
ES2906885T3 (es) Forma cristalina de compuestos de tetraciclina sustituidos con 9-aminometilo y método de preparación para la misma
ES2794568T3 (es) Forma cristalina de un inhibidor del receptor de andrógenos y procedimiento de preparación del mismo